Qiang Gong
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2014First federal award
$12.0MFederal grants as PI20 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
20 awards · $12.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 27, 2023 | NIH | SBIR Phase II Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases | $756K | APTITUDE MEDICAL SYSTEMS INC |
| May 16, 2022 | NIH | SBIR Phase II Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases | $744K | APTITUDE MEDICAL SYSTEMS INC |
| May 1, 2022 | NIH | SBIR Phase II Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases | $1.5M | APTITUDE MEDICAL SYSTEMS INC |
| Sep 1, 2021 | NIH | SBIR Phase I Developing a multivalent agent for long-lasting treatment of diabetic macular edema | $225K | APTITUDE MEDICAL SYSTEMS INC |
| Aug 10, 2021 | NIH | SBIR Phase II Developing a multivalent agent for long-lasting treatment of diabetic macular edema | $225K | APTITUDE MEDICAL SYSTEMS INC |
| Jul 28, 2021 | NIH | SBIR Phase II Targeting SDF-1 for effective wet AMD treatment | $805K | APTITUDE MEDICAL SYSTEMS INC |
| Aug 1, 2020 | NIH | SBIR Phase II Targeting SDF-1 for effective wet AMD treatment | $1.7M | APTITUDE MEDICAL SYSTEMS INC |
| Jul 27, 2020 | NIH | SBIR Phase II Targeting SDF-1 for effective wet AMD treatment | $912K | APTITUDE MEDICAL SYSTEMS INC |
| Feb 21, 2020 | NIH | SBIR Phase II Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases | $225K | APTITUDE MEDICAL SYSTEMS INC |
| Sep 30, 2019 | NIH | SBIR Phase I Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy | $225K | APTITUDE MEDICAL SYSTEMS INC |
| Sep 17, 2019 | NIH | SBIR Phase II Targeting SDF-1 for effective wet AMD treatment | $283K | APTITUDE MEDICAL SYSTEMS INC |
| Sep 13, 2019 | NIH | SBIR Phase I Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy | $225K | APTITUDE MEDICAL SYSTEMS INC |
| Sep 22, 2018 | NIH | SBIR Phase I Topical delivery of therapeutic aptamers | $293K | APTITUDE MEDICAL SYSTEMS INC |
| Sep 30, 2017 | NIH | SBIR Phase I Targeting SDF for effective wet AMD treatment | $250K | APTITUDE MEDICAL SYSTEMS INC |
| Sep 7, 2017 | NIH | SBIR Phase I Targeting SDF-1 for effective wet AMD treatment | $250K | APTITUDE MEDICAL SYSTEMS INC |
| May 1, 2017 | NIH | SBIR Phase I Fully modified bispecific aptamer for effective wet AMD combination treatment | $203K | APTITUDE MEDICAL SYSTEMS INC |
| Apr 14, 2017 | NIH | SBIR Phase I Fully modified bispecific aptamer for effective wet AMD combination treatment | $203K | APTITUDE MEDICAL SYSTEMS INC |
| Nov 24, 2015 | NIH | SBIR Phase II Particle display: a new paradigm in high throughput discovery of ultra-high perfo | $625K | APTITUDE MEDICAL SYSTEMS INC |
| Dec 5, 2014 | NIH | SBIR Phase II Particle display: a new paradigm in high throughput discovery of ultra-high perfo | $1.5M | APTITUDE MEDICAL SYSTEMS INC |
| Nov 27, 2014 | NIH | SBIR Phase II Particle display: a new paradigm in high throughput discovery of ultra-high perfo | $873K | APTITUDE MEDICAL SYSTEMS INC |
Peer ranks
Federal funding#40
Awards as PI#18
Patents#273
Companies
- APTITUDE MEDICAL SYSTEMS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.